Molecular Partners (NASDAQ:MOLN) Releases Earnings Results, Beats Estimates By $0.11 EPS

Molecular Partners (NASDAQ:MOLN) announced its quarterly earnings data on Thursday. The company reported ($0.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.11, Zacks reports. Molecular Partners had a negative return on equity of 39.31% and a negative net margin of 1,043.01%.

Molecular Partners Stock Performance

Shares of Molecular Partners stock remained flat at $4.90 during trading on Thursday. The stock had a trading volume of 1,459 shares, compared to its average volume of 4,072. The company has a market capitalization of $197.78 million, a PE ratio of -2.28 and a beta of 1.06. The business’s fifty day moving average is $5.12 and its two-hundred day moving average is $5.39. Molecular Partners has a fifty-two week low of $3.32 and a fifty-two week high of $12.70.

Molecular Partners Company Profile

Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia.